AskFiona AI is the first point of contact for cancer patients seeking information about clinical trials. She is an empathetic and knowledgeable chatbot that provides general information about clinical trials, their purpose, and the overall process. AskFiona AI also assesses patient eligibility for more in-depth information and escalates them to DrArturo AI if appropriate.
AskFiona AI - Key Features
Massive Bio is proud to present our ChatGPT-powered chatbot platform, designed to provide comprehensive information and support for cancer patients, referring physicians, and site principal investigators along with their research coordinators. Our chatbot platform consists of two primary personas: AskFiona AI and DrArturo AI. These novel and best-in-class tools will be integrated into the already existing SYNERGY-AI Clinical Trial Matching Solution.
- Approachable and supportive, putting users at ease
- Designed to establish trust and rapport with patients
- Overview of clinical trials, their purpose, and potential benefits
- Guidance on the overall process, from screening to participation
- Asks targeted questions to determine a user’s potential eligibility for clinical trials
- Escalates eligible users to DrArturo AI for in-depth trial information
- Intuitive, easy-to-navigate layout
- Accessible on multiple devices, including smartphones, tablets, and computers
- Communicates with users in multiple languages to facilitate understanding and accessibility
- Provides prompt and accurate responses to user inquiries
- Reduces wait time for information compared to traditional channels
- Continuously improves its knowledge base and response accuracy through machine learning algorithms
- Stays updated with the latest information on cancer clinical trials
- Complies with data protection regulations and maintains user confidentiality
- Ensures that sensitive information is handled securely and responsibly
About Massive Bio
Massive Bio empowers cancer patients to find their best treatment options, using artificial intelligence to improve equitable access and precision targeting for clinical trial matching, drug matching, and drug development. Massive Bio combines its best-in-class AI platform with technology-enabled services to remove barriers in clinical trial enrollment, value-based oncology decisions, and data-driven cancer treatment. The company serves more than two dozen pharmaceutical companies, contract research organizations, and hospital networks, and has been awarded an SBIR contract by the National Cancer Institute. Massive Bio was founded in 2015 by clinical, technology, and M&A executives, and has a global presence with nearly 100 people in 12 countries.